Concord Drugs Ltd vs Shukra Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Concord Drugs Ltd is ₹ 79.5 as of 18 May 13:20 . The P/E Ratio of Concord Drugs Ltd changed from 15.9 on March 2022 to 91.4 on March 2025 . This represents a CAGR of 54.84% over 4 yearsThe P/E Ratio of Shukra Pharmaceuticals Ltd changed from 0 on March 2022 to 0 on March 2025 . This represents a CAGR of 0.0% over 4 years The Market Cap of Concord Drugs Ltd changed from ₹ 25.36 crore on March 2022 to ₹ 31.08 crore on March 2025 . This represents a CAGR of 5.22% over 4 yearsThe Market Cap of Shukra Pharmaceuticals Ltd changed from ₹ 0 crore on March 2022 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 4 years The revenue of Concord Drugs Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 16.99 crore. This represent the decline of -100% The revenue of Shukra Pharmaceuticals Ltd for the Mar '26 is ₹ 7.27 crore as compare to the Dec '25 revenue of ₹ 39.95 crore. This represent the decline of -81.8% The ebitda of Concord Drugs Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0.94 crore. This represent the decline of -100% The ebitda of Shukra Pharmaceuticals Ltd for the Mar '26 is ₹ 1.65 crore as compare to the Dec '25 ebitda of ₹ 27.95 crore. This represent the decline of -94.1% The net profit of Concord Drugs Ltd changed from ₹ 0.23 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Shukra Pharmaceuticals Ltd changed from ₹ 3.16 crore to ₹ -1.72 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of Concord Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Shukra Pharmaceuticals Ltd changed from 10.47 % on March 2022 to 4.57 % on March 2025 . This represents a CAGR of -18.72% over 4 years .

About Concord Drugs Ltd

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved.
The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad.
State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality. The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.

About Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Limited, formerly known Relish Pharmaceuticals Limited was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016.
The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing. The company provides varieties of products to the clientele.
Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.

FAQs for the comparison of Concord Drugs Ltd and Shukra Pharmaceuticals Ltd

Which company has a larger market capitalization, Concord Drugs Ltd or Shukra Pharmaceuticals Ltd?

Market cap of Concord Drugs Ltd is 106 Cr while Market cap of Shukra Pharmaceuticals Ltd is 1,374 Cr

What are the key factors driving the stock performance of Concord Drugs Ltd and Shukra Pharmaceuticals Ltd?

The stock performance of Concord Drugs Ltd and Shukra Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Drugs Ltd and Shukra Pharmaceuticals Ltd?

As of May 18, 2026, the Concord Drugs Ltd stock price is INR ₹81.0. On the other hand, Shukra Pharmaceuticals Ltd stock price is INR ₹31.4.

How do dividend payouts of Concord Drugs Ltd and Shukra Pharmaceuticals Ltd compare?

To compare the dividend payouts of Concord Drugs Ltd and Shukra Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.